Sarah Quinn
Nurse Practitioner · Reno, NVNPI 1891126512
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 51 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $565 and has fallen 91.7% since, to $47 in 2025.
Across 51 payments — averaging $35.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$383
- Vifor Pharma, Inc.$364
- GSK$223
- AstraZeneca$198
- Otsuka America Pharmaceutical, Inc.$108
- Boehringer Ingelheim$106
- plus $407 from 16 others
Across 9 payments — averaging $188.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$2K
What the payments were for
- Food & beverage$1,77399%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 11 | $383 |
| Vifor Pharma, Inc. | 6 | $364 |
| GSK | 2 | $223 |
| AstraZeneca | 6 | $198 |
| Otsuka America Pharmaceutical, Inc. | 4 | $108 |
| Boehringer Ingelheim | 1 | $106 |
| Mallinckrodt Hospital Products Inc. | 3 | $62 |
| Calliditas Therapeutics US Inc. | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Fresenius USA Marketing, Inc. | 2 | $26 |
| Travere Therapeutics, Inc. | 2 | $26 |
| Bayer | 1 | $24 |
| Abbott | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Tactile Systems Technology Inc | 1 | $22 |
| Aurinia Pharma U.S., Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Chiesi USA, Inc. | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| OPKO Pharmaceuticals, LLC | 1 | $15 |
| Corcept Therapeutics | 1 | $15 |
| UCB, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,788 in reported general payments places this provider in the 80th percentile of 933 nurse practitioner providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 16 | $30,856 |
| Lanthanum Carbonate | 11 | $13,907 |
| Sevelamer Carbonate | 20 | $3,773 |
| Cinacalcet Hcl | 14 | $2,219 |
| Potassium Chloride | 31 | $858 |
| Allopurinol | 26 | $299 |
| Furosemide | 29 | $287 |
| Torsemide | 11 | $242 |
| Losartan Potassium | 23 | $175 |
| Carvedilol | 17 | $140 |
| Tamsulosin Hcl | 11 | $139 |
| Gabapentin | 12 | $116 |
| Calcitriol | 13 | $108 |
| Atorvastatin Calcium | 17 | $106 |
| Spironolactone | 15 | $70 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $26 | $30,85616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 933 nurse practitioner providers in Nevada.
Other nurse practitioner in Reno
- Melissa DelamoraReno$20K
- Darian ThorpReno$18K
- Mary Beth MedinaReno$11K
- Kristen BowmanReno$10K
- Laura HayReno$8K
- Laura HarshReno$7K
- Mary HelmreichReno$7K
- Rhonda StrunkReno$7K
- Rachael HueftleReno$7K
- Rhonda NavarroReno$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.